ASRT - Assertio Therapeutics Inc Stock Price, Fair Value and News

1.08USD+0.06 (+5.88%)Delayed

Market Summary

USD1.08+0.06

Delayed

5.88%

ASRT Stock Price

View Fullscreen

ASRT RSI Chart

ASRT Valuation

Market Cap

102.7M

Price/Earnings (Trailing)

-0.31

Price/Sales (Trailing)

0.72

EV/EBITDA

-0.27

Price/Free Cashflow

3.04

ASRT Price/Sales (Trailing)

ASRT Profitability

EBT Margin

-177.99%

Return on Equity

-247.57%

Return on Assets

-118.09%

Free Cashflow Yield

32.87%

ASRT Fundamentals

ASRT Revenue

Revenue (TTM)

142.1M

Rev. Growth (Yr)

-23.59%

Rev. Growth (Qtr)

-1.63%

ASRT Earnings

Earnings (TTM)

-333.0M

Earnings Growth (Yr)

-29.45%

Earnings Growth (Qtr)

92.14%

Breaking Down ASRT Revenue

Last 7 days

12.5%

Last 30 days

38.5%

Last 90 days

27.1%

Trailing 12 Months

-84.7%

How does ASRT drawdown profile look like?

ASRT Financial Health

Current Ratio

1.87

Debt/Equity

0.29

Debt/Cashflow

0.89

ASRT Investor Care

Shares Dilution (1Y)

70.89%

Diluted EPS (TTM)

-4.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	142.1M	0	0	0
2023	162.2M	168.0M	169.4M	152.1M
2022	120.7M	130.5M	139.2M	156.2M
2021	112.2M	117.0M	107.9M	111.0M
2020	198.7M	167.9M	137.1M	106.3M
2019	0	0	0	229.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Assertio Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 14, 2024	tyree james l	sold	-11,462	1.1182	-10,251	-
Feb 21, 2024	patel ajay	acquired	-	-	17,151	svp and cfo
Feb 21, 2024	schwichtenberg paul	sold (taxes)	-6,719	0.79	-8,506	svp, cco
Feb 21, 2024	schlessinger sam	sold (taxes)	-6,719	0.79	-8,506	svp, general counsel
Feb 21, 2024	schlessinger sam	acquired	-	-	17,151	svp, general counsel
Feb 21, 2024	schwichtenberg paul	acquired	-	-	17,151	svp, cco
Feb 21, 2024	patel ajay	sold (taxes)	-6,719	0.79	-8,506	svp and cfo
Feb 11, 2024	schwichtenberg paul	acquired	-	-	47,348	see remarks
Feb 11, 2024	schlessinger sam	acquired	-	-	18,939	svp, general counsel
Feb 11, 2024	patel ajay	acquired	-	-	47,348	svp and cfo

Which funds bought or sold ASRT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-37.34	-6,849	8,780	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-54.3	-38,471	26,705	-%
May 16, 2024	ALETHEA CAPITAL MANAGEMENT, LLC	reduced	-3.99	-19,939	123,220	0.10%
May 15, 2024	Nantahala Capital Management, LLC	reduced	-39.16	-7,412,090	8,893,510	0.51%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-59.95	-136,279	76,297	-%
May 15, 2024	Gotham Asset Management, LLC	reduced	-41.55	-13,382	14,733	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	reduced	-7.45	-222,282	1,083,560	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	sold off	-100	-6,206,000	-	-%
May 15, 2024	Squarepoint Ops LLC	reduced	-24.04	-27,219	58,119	-%
May 15, 2024	Engineers Gate Manager LP	reduced	-64.52	-35,825	16,714	-%

Are Funds Buying or Selling ASRT?

Are funds buying ASRT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ASRT

No. of Funds

Unveiling Assertio Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	continental general insurance co	-	0	SC 13G/A
Feb 14, 2024	armistice capital, llc	6.13%	5,800,000	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	8.0%	7,619,440	SC 13G
Feb 13, 2024	vanguard group inc	5.15%	4,878,543	SC 13G
Jan 26, 2024	blackrock inc.	6.9%	6,574,483	SC 13G
May 05, 2023	continental general insurance co	6.7%	96,426	SC 13G
Jan 27, 2022	highbridge capital management llc	0%	0	SC 13G/A
Feb 16, 2021	d. e. shaw & co, l.p.	2.2%	2,321,422	SC 13G/A
Feb 11, 2021	renaissance technologies llc	6.08%	6,522,314	SC 13G/A
Feb 04, 2021	ci investments inc.	5.63%	6,258,862	SC 13G/A

Recent SEC filings of Assertio Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	PX14A6G	PX14A6G
May 06, 2024	10-Q	Quarterly Report
May 06, 2024	8-K	Current Report
Apr 24, 2024	EFFECT	EFFECT
Apr 19, 2024	ARS	ARS
Apr 19, 2024	DEF 14A	DEF 14A
Apr 09, 2024	3	Insider Trading

Peers (Alternatives to Assertio Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Assertio Therapeutics Inc News

Latest updates

Assertio Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Revenue	-1.6%	32,448	32,985	35,627	40,991	42,466	50,352	34,212	35,131	36,538	33,329	25,472	25,373	26,839	30,176	34,565	20,617	20,917	38,032	55,147	57,203
Costs and Expenses	-43.7%	36,785	65,314	263,898	28,571	37,822	39,730	27,778	24,340	24,979	25,347	19,538	37,374	19,332	63,272	41,240	46,369	37,549	-	65,280	53,585
S&GA Expenses	-22.7%	18,524	23,958	21,005	16,771	16,904	13,704	11,900	10,543	10,638	11,264	9,013	24,040	8,324	21,272	27,607	28,131	27,314	-	36,117	24,755
R&D Expenses	-28.4%	733	1,024	1,316	503	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	-7.4%	-1.56*	-1.45*	-1.07*	0.30*	0.30*	0.42*	0.47*	0.51*	0.37*	0.35*	-0.02*	-0.14*	-	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	4,398	-	-	1,122	-1,163	-	-	2,327	2,437	2,495	2,605	2,684	2,598	3,050	1,604	8,674	-	13,872	14,842
Income Taxes	-99.5%	132	25,459	50,700	3,860	-2,110	-79,975	210	593	713	434	46.00	-300	548	-10,995	1,050	-9,472	2,048	-	-1,715	1,141
Earnings Before Taxes	86.3%	-4,378	-31,905	-228,885	12,330	-5,594	8,578	4,384	8,427	9,777	5,041	3,783	-14,469	5,092	-35,348	-9,472	-43,971	43,278	-	1,616	-12,464
EBT Margin	-6.5%	-1.78*	-1.67*	-1.26*	0.12*	0.10*	0.20*	0.20*	0.21*	0.03*	0.00*	-0.38*	-0.46*	-	-	-	-	-	-	-	-
Net Income	92.1%	-4,510	-57,384	-279,544	8,470	-3,484	88,553	4,174	7,834	9,064	4,607	3,737	-14,169	4,544	-24,353	-10,522	-34,499	41,230	-192,626	3,331	-13,605
Net Income Margin	-7.4%	-2.34*	-2.18*	-1.10*	0.58*	0.60*	0.70*	0.18*	0.19*	0.03*	-0.01*	-0.28*	-0.38*	-	-	-	-	-	-	-	-
Free Cashflow	32.1%	7,408	5,607	2,579	18,327	22,443	26,423	10,045	14,377	27,373	4,078	4,654	964	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-1.6%	282	286	380	405	414	414	323	322	339	327	299	312	325	303	333	346	527
Current Assets	0.8%	172	171	185	134	138	132	126	117	125	103	113	119	124	94.00	104	135	104
Cash Equivalents	9.9%	81.00	73.00	77.00	70.00	69.00	65.00	65.00	52.00	61.00	37.00	59.00	54.00	61.00	21.00	35.00	59.00	42.00
Inventory	2.4%	39.00	38.00	43.00	19.00	16.00	14.00	14.00	12.00	9.00	7.00	5.00	7.00	9.00	12.00	13.00	25.00	3.00
Net PPE	-8.6%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	4.00	7.00	3.00
Goodwill	-	-	-	20.00	-	-	-	-	-	-	-	-	-	-	-	9.00	9.00	-
Liabilities	-0.6%	147	148	187	151	164	188	188	194	227	224	202	220	220	248	257	261	469
Current Liabilities	-1.1%	92.00	93.00	114	79.00	95.00	95.00	92.00	116	139	135	100	117	109	133	131	134	185
Long Term Debt	0.3%	39.00	39.00	39.00	38.00	38.00	66.00	66.00	50.00	61.00	61.00	66.00	67.00	72.00	72.00	77.00	92.00	271
LT Debt, Current	-	-	-	-	-	0.00	0.00	-	-	-	12.00	-	-	-	12.00	-	-	80.00
LT Debt, Non Current	-100.0%	-	39.00	39.00	38.00	38.00	66.00	66.00	50.00	61.00	61.00	66.00	67.00	72.00	72.00	77.00	92.00	271
Shareholder's Equity	-2.5%	134	138	193	254	251	226	135	128	112	102	97.00	92.00	105	56.00	76.00	85.00	58.00
Retained Earnings	-0.7%	-656	-651	-594	-314	-323	-319	-408	-412	-420	-429	-433	-437	-423	-427	-403	-393	-399
Additional Paid-In Capital	0.1%	791	790	787	569	574	545	543	541	532	532	531	530	529	483	480	478	458
Shares Outstanding	0.5%	95.00	95.00	95.00	57.00	56.00	48.00	48.00	46.00	45.00	45.00	43.00	41.00	-	-	-	-	-
Float	-	-	-	-	296	-	-	-	140	-	-	-	68.00	-	-	-	90.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	31.6%	7,508	5,707	2,579	18,601	22,717	26,697	10,045	14,430	27,426	4,131	4,654	964	-4,226	-5,982	-14,431	-20,096	-25,063	-	-	-
Share Based Compensation	-54.3%	1,207	2,642	1,865	2,205	2,446	2,388	2,400	1,734	982	949	867	957	772	3,886	1,511	3,593	1,934	-	-	-
Cashflow From Investing	100.0%	-	-239	4,144	-703	-105	-25,784	-371	-16,114	-404	-18,525	-	-	-	-	-1.00	63,766	449,036	-	-	-
Cashflow From Financing	97.7%	-206	-8,915	-10.00	-16,326	-18,950	-798	2,888	-7,441	-2,443	-7,522	-356	-7,569	44,473	-7,969	-10,234	-90,240	-360,107	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ASRT Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 32,448	$ 42,466
Costs and expenses:
Cost of sales	11,177	5,467
Research and development expenses	733	0
Selling, general and administrative expenses	18,524	16,904
Change in fair value of contingent consideration	0	9,167
Amortization of intangible assets	5,631	6,284
Restructuring charges	720	0
Total costs and expenses	36,785	37,822
(Loss) income from operations	(4,337)	4,644
Other (expense) income:
Debt-related expenses	0	(9,918)
Interest expense	(757)	(1,122)
Other gain	716	802
Total other expense	(41)	(10,238)
Net loss before income taxes	(4,378)	(5,594)
Income tax (expense) benefit	(132)	2,110
Net loss and comprehensive loss	$ (4,510)	$ (3,484)
Basic net loss per share (in dollars per share)	$ (0.05)	$ (0.07)
Diluted net loss per share (in dollars per share)	$ (0.05)	$ (0.07)
Shares used in computing basic net loss per share (in shares)	94,980	51,005
Shares used in computing diluted net loss per share (in shares)	94,980	51,005
Product sales, net
Revenues:
Total revenues	$ 31,862	$ 41,769
Royalties and milestones
Revenues:
Total revenues	$ 586	$ 697

ASRT Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 80,743	$ 73,441
Accounts receivable, net	42,610	47,663
Inventories, net	38,602	37,686
Prepaid and other current assets	10,519	12,272
Total current assets	172,474	171,062
Property and equipment, net	704	770
Intangible assets, net	105,701	111,332
Other long-term assets	3,086	3,255
Total assets	281,965	286,419
Current liabilities:
Accounts payable	15,650	13,439
Accrued rebates, returns and discounts	57,870	58,137
Accrued liabilities	15,401	18,213
Contingent consideration, current portion	2,700	2,700
Other current liabilities	823	954
Total current liabilities	92,444	93,443
Long-term debt	38,621	38,514
Other long-term liabilities	16,406	16,459
Total liabilities	147,471	148,416
Commitments and contingencies (Note 15)
Shareholders’ equity:
Common stock, $0.0001 par value, 200,000,000 shares authorized; 95,115,452 and 94,668,523 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.	9	9
Additional paid-in capital	790,538	789,537
Accumulated deficit	(656,053)	(651,543)
Total shareholders’ equity	134,494	138,003
Total liabilities and shareholders' equity	$ 281,965	$ 286,419

About Assertio Therapeutics Inc

Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, rheumatology, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

CEO	Mr. Daniel A. Peisert
WEBSITE	assertiotx.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	30

Assertio Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Assertio Therapeutics Inc? What does ASRT stand for in stocks?

ASRT is the stock ticker symbol of Assertio Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Assertio Therapeutics Inc (ASRT)?

As of Fri May 17 2024, market cap of Assertio Therapeutics Inc is 102.73 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ASRT stock?

You can check ASRT's fair value in chart for subscribers.

What is the fair value of ASRT stock?

You can check ASRT's fair value in chart for subscribers. The fair value of Assertio Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Assertio Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ASRT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Assertio Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ASRT is over valued or under valued. Whether Assertio Therapeutics Inc is cheap or expensive depends on the assumptions which impact Assertio Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ASRT.

What is Assertio Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ASRT's PE ratio (Price to Earnings) is -0.31 and Price to Sales (PS) ratio is 0.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ASRT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Assertio Therapeutics Inc's stock?

In the past 10 years, Assertio Therapeutics Inc has provided -0.309 (multiply by 100 for percentage) rate of return.